BiotechTube

AG013

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Oral Mucositis

Conditions

Oral Mucositis

Trial Timeline

Jul 18, 2017 → Jul 13, 2020

NCT ID
NCT03234465

About AG013

AG013 is a phase 2 stage product being developed by Oragenics for Oral Mucositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03234465. Target conditions include Oral Mucositis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03234465Phase 2Terminated

Competing Products

20 competing products in Oral Mucositis

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
69
AL001AlectorPhase 2
44
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
44
Micafungin + FluconazoleAstellas PharmaPhase 3
77
micafungin + caspofunginAstellas PharmaPhase 3
77
Erlotinib + PlaceboAstellas PharmaPhase 3
77
AmifostineSun PharmaceuticalApproved
85
exenatide + Other antidiabetic therapiesEli LillyPre-clinical
23
Teriparatide 20 mcgEli LillyPhase 3
77
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
41
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
52
tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
85
Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved
85
galantamine hydrobromideJohnson & JohnsonPhase 2
52
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
77
Camrelizumab + Camrelizumanb plus TPFJiangsu Hengrui MedicinePhase 2
52
Camrelizumab plus TP + TPJiangsu Hengrui MedicinePhase 3
77
AZD1981 + Neovletta 21/28 + Placebo AZD1981AstraZenecaPhase 1
33
DurvalumabAstraZenecaPhase 1/2
41
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
33

Other Products from Oragenics

Neurosteroid enantiomerPhase 2
44